CreoSG Co.,Ltd.

040350.KQ·KOSDAQ

Compare

2,425.00−5.00 (−0.21%)today

At close: Nov 4, 3:30 PM KST · May be delayed up to 20 min · KRW

Key statistics

Previous close2,430.00

Open2,480.00

Day range2,290.002,545.00

52-week range2,290.0012,800.00

Off day high−4.72%

Off 52-week high−81.05%

Volume76.46K

Avg. volume (3M)94.79K

Market cap47.23B

EPS (TTM)—

Forward P/E—

P/E ratio (TTM)—

Dividend yield—

Beta (5Y)—

Shares outstanding19.48M

Short interest—

Earnings dateAug 12, 2025 (est.)

Analyst target—

Profit margin—

Related companies

Compare ›

Companies on KOSDAQ of a similar market value (48.50B).

Company	Mkt cap	Price	Today
SGA Solutions Co.,Ltd.184230.KQ · Software - Application	47.65B	2,530.00	−8.50%
CosLeaguer Global Co., Ltd.043710.KQ	50.55B	2,920.00	+4.66%
Sangji Construction, Inc.042940.KQ · Engineering & Construction	34.05B	4,805.00	−3.42%
Jin Yang Pharmaceutical Co., Ltd.007370.KQ · Drug Manufacturers - Specialty & Generic	48.27B	3,415.00	−0.44%
Dongwoo Farm To Table Co ., Ltd088910.KQ · Packaged Foods	48.77B	1,896.00	+0.48%
KL-Net Corp.039420.KQ · Information Technology Services	47.83B	2,400.00	−1.44%
PonyLink Co., Ltd.064800.KQ · Software - Application	51.55B	2,045.00	+3.81%
WIZIT Co., Ltd.036090.KQ · Electronic Components	46.42B	1,095.00	−1.97%

From the 4SEARCH.business instruments index: what each company does (its business description), its industry, size, headquarters and the markets it serves; and from a year of daily prices, which move together. Prices may be delayed up to 20 min.

Latest news

All 040350.KQ news ›

The Asia Business Daily·Oct 22Positive

CreoSG Secures South Korean Patent for Recombinant VSV-Based COVID-19 Vaccine

Published 22 Oct.2026 14:29(KST) CreoSG has secured a South Korean patent for COVID-19 vaccine technology using its proprietary recombinant VSV (Vesicular Stomatitis Virus) platform. The company plans to strengthen the fou

MRNA PFE

From the 4Search news index, newest first.

Earnings

Reported EPS
Estimate

Next report: Tue, Aug 12, 2025 (estimated)

Quarterly results

Financials ›

Revenue
Net income
Net margin 56.2% (Q2 '26)

Prices may be delayed up to 15 min. Not investment advice.

Track record

Leaderboard ›

Days on the list	30 d	1 yr	Best
Trending	0	0	—

Not eligible for Gainers, Losers, Most active (U.S. stocks worth $2 billion or more only).

Not eligible for Small-cap gainers, Aggressive small caps (U.S. stocks worth under $2 billion only).

Not eligible for Growth tech (U.S. technology stocks only).

Not eligible for Undervalued large caps (U.S. stocks worth $10 billion or more only).

A day counts when it ranked in the top 25 of a list. Tracked since Oct 10, 2026.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance